These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7178231)

  • 1. Response to maprotiline treatment in depressive patients relationship to urinary MHPG excretion and plasma drug level.
    Gaertner HJ; Golfinopoulos G; Breyer-Pfaff U
    Pharmacopsychiatria; 1982 Sep; 15(5):170-4. PubMed ID: 7178231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHPG as a predictor of antidepressant response to imipramine and maprotiline.
    Rosenbaum AH; Schatzberg AF; Maruta T; Orsulak PJ; Cole JO; Grab EL; Schildkraut JJ
    Am J Psychiatry; 1980 Sep; 137(9):1090-2. PubMed ID: 7425162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary MHPG excretion and treatment with desipramine or amitriptyline: prediction of response, effect of treatment, and methodological hazards.
    Veith RC; Bielski RJ; Bloom V; Fawcett JA; Narasimhachari N; Friedel RO
    J Clin Psychopharmacol; 1983 Feb; 3(1):18-27. PubMed ID: 6833519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine.
    Ko HC; Lu RB; Shiah IS; Hwang CC
    Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward a biochemical classification of depressive disorders. III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline.
    Schatzberg AF; Rosenbaum AH; Orsulak PJ; Rohde WA; Maruta T; Kruger ER; Cole JO; Schildkraut JJ
    Psychopharmacology (Berl); 1981; 75(1):34-8. PubMed ID: 6795656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary 3-methoxy, 4-hydroxyphenylethylene glycol and therapeutic response to maprotiline and indalpine in major depression.
    Loo H; Benkelfat C; Vanelle JM; Dennis T; Poirier MF; Olie JP; Scatton B
    J Neural Transm; 1986; 66(1):47-58. PubMed ID: 3734775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blood concentrations of maprotiline in depressive patients].
    Rouillon F; Sioufi A; Serrurier D; Mizon JP; Plaquet R; Richard JB; Riche C; Bourin M; Kergueris MF; Besançon G
    Encephale; 1988; 14(4):299-305. PubMed ID: 3058453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic superiority of maprotiline versus doxepin in geriatric depression.
    Gwirtsman HE; Ahles S; Halaris A; DeMet E; Hill MA
    J Clin Psychiatry; 1983 Dec; 44(12):449-53. PubMed ID: 6361005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) excretion in depression.
    Steiner M; Radwan M; Elizur A; Blum I; Atsmon A; Davidson S
    Jpn J Exp Med; 1979 Apr; 49(2):95-9. PubMed ID: 480680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary MHPG is not a good predictor of antidepressive drug response.
    Puzyński S; Rode A; Bidziński A; Mrozek S; Załuska M
    Pol J Pharmacol Pharm; 1984; 36(4):329-35. PubMed ID: 6527968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative speed of onset of the antidepressant effect of maprotiline.
    Silverstone T
    Clin Ther; 1981; 3(5):374-81. PubMed ID: 7471133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alprazolam response in major depression: relationship with urinary levels of MHPG-sulfate.
    Gattaz WF; Bauer K; Rost W; Hübner CK; Müller WE
    Pharmacopsychiatry; 1988 Nov; 21(6):374-5. PubMed ID: 3244771
    [No Abstract]   [Full Text] [Related]  

  • 13. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants.
    Mooney JJ; Schatzberg AF; Cole JO; Samson JA; Waternaux C; Gerson B; Pappalardo KM; Schildkraut JJ
    J Clin Psychopharmacol; 1991 Dec; 11(6):339-43. PubMed ID: 1770151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do urinary MHPG and plasma drug levels correlate with response to amitriptyline therapy?
    Gaertner HJ; Kreuter F; Scharek G; Wiatr G; Breyer-Pfaff U
    Psychopharmacology (Berl); 1982; 76(3):236-9. PubMed ID: 6808543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maprotiline in affective illness. Plasma concentration and clinical response.
    Norman TR; Burrows GD; Maguire KP; McIntyre IM; Scoggins BA
    J Affect Disord; 1983 May; 5(2):147-54. PubMed ID: 6222094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biological parameters as predictors for antidepressant drug responses in depressed patients.
    Fähndrich E
    Pharmacopsychiatria; 1983 Nov; 16(6):179-85. PubMed ID: 6665027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maprotiline versus imipramine and placebo in neurotic depression.
    van der Velde CD
    J Clin Psychiatry; 1981 Apr; 42(4):138-41. PubMed ID: 7009592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study.
    Kasper S; Voll G; Vieira A; Kick H
    Pharmacopsychiatry; 1990 May; 23(3):135-42. PubMed ID: 2115680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimipramine and maprotiline: antidepressant, anxiolytic, and cardiotoxic comparison.
    Pecknold JC; Familamiri P; McClure DJ; Elie R; Chang H
    J Clin Psychiatry; 1985 May; 46(5):166-71. PubMed ID: 2859273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind trial comparing mianserin and maprotiline in depressed inpatients.
    Palha AP; Ferreira L; Abreu-Lima C; Ramalhão C; Fernandes R
    Clin Ther; 1985; 7(5):584-92. PubMed ID: 3902238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.